The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aprinoia Therapeutics's share price is $0.00.
Aprinoia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.32. Hence, Aprinoia Therapeutics's PS Ratio for today is 0.00.
The historical rank and industry rank for Aprinoia Therapeutics's PS Ratio or its related term are showing as below:
APRI's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.165 * Ranked among companies with meaningful PS Ratio only.
Aprinoia Therapeutics (NAS:APRI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprinoia Therapeutics PS Ratio Chart
Aprinoia Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
PS Ratio
0.00
0.00
0.00
Aprinoia Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
PS Ratio
0.00
0.00
0.00
0.00
0.00
APRI vs : PS Ratio Comparison
For the Biotechnology subindustry, Aprinoia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprinoia Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aprinoia Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aprinoia Therapeutics's Share Price of today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aprinoia Therapeutics (APRI) has a PS Ratio of 0.00 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' PS Ratio too high?
Aprinoia Therapeutics' current PS Ratio is 0.00.
How does Aprinoia Therapeutics' PS Ratio compare to ?
Aprinoia Therapeutics' PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current PS Ratio is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRI has been successfully added to your